Anita Vagnoni, MD
Internal Medicine · Anderson, SCNPI 1356355747
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Novartis accounts for 72.5% of it on its own, with 38 other manufacturers making up the rest. Reporting peaked in 2019 at $14,627 and has fallen 88.5% since, to $1,683 in 2025. Among internal medicine clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 377 payments — averaging $56.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$15K
- Abbott$1K
- AstraZeneca$633
- Boston Scientific$448
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$400
- Pfizer$344
- plus $3K from 33 others
What the payments were for
- Consulting fees$7924%
- Speaking & faculty fees$12,14457%
- Travel & lodging$1,2276%
- Food & beverage$6,84432%
- Education$1221%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 71 | $15,312 |
| Abbott | 63 | $1,275 |
| AstraZeneca | 21 | $633 |
| Boston Scientific | 24 | $448 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 30 | $400 |
| Pfizer | 16 | $344 |
| Novo Nordisk | 20 | $309 |
| Merck | 17 | $284 |
| Boehringer Ingelheim | 11 | $216 |
| Bayer | 11 | $208 |
| Lilly USA, LLC | 10 | $157 |
| Cvrx, Inc. | 8 | $155 |
| Biosense Webster, Inc. | 6 | $113 |
| Johnson & Johnson | 8 | $105 |
| AbbVie | 4 | $91 |
| Dexcom, Inc. | 4 | $91 |
| Edwards Lifesciences | 3 | $83 |
| Atricure, Inc. | 2 | $82 |
| Exact Sciences | 5 | $78 |
| Amgen | 4 | $78 |
| Phathom Pharmaceuticals, Inc. | 5 | $70 |
| Medtronic(2 entities) | 3 | $54 |
| Eisai Inc. | 2 | $53 |
| Lexicon Pharmaceuticals, Inc. | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 3 | $48 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| Alnylam Pharmaceuticals Inc. | 2 | $45 |
| Impulse Dynamics (USA) Inc. | 3 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| GSK | 2 | $30 |
| Arbor Pharmaceuticals, Inc. | 2 | $29 |
| Astellas Pharma US Inc | 1 | $24 |
| Kestra Medical Technology Services, Inc. | 1 | $24 |
| Gilead | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Portola Pharmaceuticals, LLC | 1 | $19 |
| Lundbeck LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$14,203
- CARDIOMEMS$180
- BREZTRI$129
- AIRSUPRA$129
- VYNDAQEL$110
How this compares
$21,129 in reported general payments places this provider in the 95th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 220 | $190,135 |
| JardianceEmpagliflozin | 158 | $125,890 |
| FarxigaDapagliflozin Propanediol | 70 | $51,738 |
| EliquisApixaban | 46 | $40,358 |
| VerquvoVericiguat | 18 | $11,771 |
| Bumetanide | 77 | $2,975 |
| Furosemide | 262 | $1,649 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 35 | $1,205 |
| Spironolactone | 208 | $1,061 |
| Metoprolol Succinate | 96 | $1,028 |
| Carvedilol | 127 | $817 |
| Eplerenone | 14 | $653 |
| Atropine Sulfate | 11 | $623 |
| Potassium Chloride | 28 | $602 |
| Atorvastatin Calcium | 58 | $548 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $15,312 | $190,135220 claims |
| Boehringer IngelheimJardiance | $216 | $125,890158 claims |
| AstraZenecaFarxiga | $633 | $51,73870 claims |
| PfizerEliquis | $344 | $40,35846 claims |
| MerckVerquvo | $284 | $11,77118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Anderson
- Carl SofleyAnderson$17K
- Jerry BackNorth Charleston$322K
- Jan BasileCharleston$278K
- Mark PurcellGreenville$165K
- John CleekCharleston$136K
- William BunnHilton Head Island$125K
- Zion LammGreenville$118K
- Bruce GrayGreenville$111K
- Leonard AlsfeldCharleston$91K
- Edward Botse-BaidooMyrtle Beach$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.